Literature DB >> 30624547

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

S Peters1, U Dafni2, M Boyer3, D De Ruysscher4, C Faivre-Finn5, E Felip6, P Garrido7, N Girard8, M Guckenberger9, J Haanen10, C Le Pechoux11, F Mornex12, M Ozsahin13, L Paz-Ares14, D Planchard15, D Raben16, S Ramalingam17, M Reck18, E Smit19, R Stahel20, A Stenzinger21, C Swanton22, S Vallone23, M C Garassino24.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30624547     DOI： 10.1093/annonc/mdy553

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  16 in total

1.  Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.

Authors:  D Isla; J de Castro; R García-Campelo; P Lianes; E Felip; P Garrido; L Paz-Ares; J M Trigo
Journal:  Clin Transl Oncol       Date:  2019-07-31       Impact factor: 3.405

2.  [Durvalumab after radiochemotherapy for locally advanced unresectable NSCLC-a breakthrough].

Authors:  Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2020-01       Impact factor: 3.621

3.  Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab.

Authors:  Alex K Bryant; Kamya Sankar; Garth W Strohbehn; Lili Zhao; Victoria Daniel; David Elliott; Nithya Ramnath; Michael D Green
Journal:  Int J Radiat Oncol Biol Phys       Date:  2022-04-19       Impact factor: 8.013

Review 4.  Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now.

Authors:  Mark G Kris; Corinne Faivre-Finn; Tiana Kordbacheh; Jamie Chaft; Jia Luo; Anne Tsao; Stephen Swisher
Journal:  Am Soc Clin Oncol Educ Book       Date:  2020-03

Review 5.  Locally Advanced, Unresectable Non-Small Cell Lung Cancer.

Authors:  Sonam Puri; Andreas Saltos; Bradford Perez; Xiuning Le; Jhanelle E Gray
Journal:  Curr Oncol Rep       Date:  2020-03-05       Impact factor: 5.075

Review 6.  Immunotherapy in non-small cell lung cancer: Update and new insights.

Authors:  Xabier Mielgo-Rubio; Eider Azkona Uribelarrea; Laura Quintanta Cortés; María Sereno Moyano
Journal:  J Clin Transl Res       Date:  2021-01-20

Review 7.  Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies.

Authors:  Sylvie Lantuejoul; Francesca Damiola; Julien Adam
Journal:  Transl Lung Cancer Res       Date:  2020-06

Review 8.  Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy.

Authors:  Lukas Käsmann; Chukwuka Eze; Julian Taugner; Olarn Roengvoraphoj; Maurice Dantes; Nina-Sophie Schmidt-Hegemann; Sanziana Schiopu; Claus Belka; Farkhad Manapov
Journal:  Radiat Oncol       Date:  2020-07-09       Impact factor: 3.481

9.  Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  P Garrido; E Conde; J de Castro; J J Gómez-Román; E Felip; L Pijuan; D Isla; J Sanz; L Paz-Ares; F López-Ríos
Journal:  Clin Transl Oncol       Date:  2019-10-09       Impact factor: 3.405

10.  Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept.

Authors:  Thierry Berghmans; Valérie Durieux; Lizza E L Hendriks; Anne-Marie Dingemans
Journal:  Front Med (Lausanne)       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.